The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake

Cancer Policy

FDA’s OCE publishes three final guidances to increase clinical trial enrollment

HHS releases government-wide policy to prohibit gain-of-function research

WHO projects new cancer cases will rise to 35 million by 2050 globally

China has outpaced the U.S. in novel cancer drug approvals since 2023, Friends analysis shows

HHS defers more than $1B in Medicaid payments to California, Minnesota pending review of high-risk claims in crackdown on fraud

HHS joins Trump’s drive to use AI to address chronic disease

Clinical Roundup

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

DNA atlas could power the next generation of AI drug discovery, Salk-led study finds

Engineered gut bacteria, BifidoSumIL-2, shows promise against pancreatic cancer

Moffitt-led team develops chemical approach to build safer precision medicines

Tecvayli + Talvey, Talvey + pomalidomide show significant survival benefit in earlier-line r/r MM, phase III trial shows

In The Clinic
Trials & Tribulations

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

Trials & Tribulations
FreeTrials & Tribulations
FreeTrials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account